Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16579976 | 0.85 | KMT2A (0.78) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL989455 | 0.83 | MEN1 (1.00) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL14046061 | 0.79 | MEN1 (0.91) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13630734 | 0.78 | KMT2A (0.55) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5553255 | 0.78 | KMT2A (0.54) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6735770 | 0.77 | KMT2A (0.53) | KMT2AMEN1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16315102 | 0.77 | MEN1 (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2SIGMAR1 | |
| SCHEMBL989456 | 0.76 | MEN1 (0.50) | KMT2AMEN1ALDH1A1SIGMAR1KDM4E | |
| SCHEMBL9832661 | 0.76 | KMT2A (0.52) | KMT2AMEN1ALDH1A1SIGMAR1KDM4E | |
| SCHEMBL2448897 | 0.75 | MEN1 (0.54) | KMT2AMEN1ALDH1A1SMN1; SMN2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
| EP-3231804-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPITAL CORPORATION (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3231804-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-2268647-B1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2017-01-25 | — | — | EP | disclosed |
| US-9005578-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | FLUOROPHARMA, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2015-04-09 | — | — | US | disclosed |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | FLUOROPHARMA, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8450466-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | THE GENERAL HOSPTIAL CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | THE GENERAL HOSPITAL CORPORATION | 2011-03-10 | — | — | US | disclosed |
| EP-2268647-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | The General Hospital Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| WO-2009117728-A2 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| EP-1569646-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054974-A2 | PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | KMT2A 2940/4885MEN1 530/4885ALDH1A1 877/4885 |
| US-10857247-B2 | Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders | APP, PSEN1, PSEN2 | KMT2A 2940/4885MEN1 530/4885ALDH1A1 877/4885 |
| US-20130315827-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | KMT2A 2940/4885MEN1 530/4885ALDH1A1 877/4885 |
| US-20150098903-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | KMT2A 2940/4885MEN1 530/4885ALDH1A1 877/4885 |
| US-20110060138-A1 | Compounds and Compositions for the Detection and Treatment of Alzheimer's Disease and Related Disorders | APP, PSEN1, PSEN2 | KMT2A 2940/4885MEN1 530/4885ALDH1A1 877/4885 |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | KMT2A 4565/4885MEN1 4561/4885ALDH1A1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.